Dr. Robert Singh, M.D.
What this data tells you about Dr. Singh
Dr. Robert Singh is a vascular surgery physician in Philadelphia, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Singh performed 403,457 Medicare services across 1,239 unique beneficiaries.
Between the years covered by Open Payments, Dr. Singh received a total of $1,015 from 14 pharmaceutical and/or device companies across 30 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in vascular surgery physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Singh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Alpha 1 proteinase inhibitor injection, 10 mg An injection of alpha 1 proteinase inhibitor, a human protein, administered in a 10 mg dose. |
202,814 | $4 | $10 |
| Inclisiran injection (Leqvio) for cholesterol | 84,634 | $9 | $23 |
| Tezepelumab injection, 1 mg An injection of tezepelumab-ekko, a medication administered in 1 mg doses. |
31,923 | $14 | $40 |
| Omalizumab injection (Xolair) for asthma/allergy | 20,551 | $30 | $76 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
15,600 | $17 | $43 |
| Injection, mepolizumab, 1 mg | 15,400 | $23 | $63 |
| Injection, tildrakizumab, 1 mg | 11,703 | $103 | $262 |
| Ocrelizumab infusion (Ocrevus) for MS | 8,101 | $43 | $113 |
| Injection, benralizumab, 1 mg | 5,401 | $130 | $325 |
| Denosumab injection (Prolia/Xgeva) | 2,044 | $17 | $33 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
2,021 | $22 | $71 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,507 | $12 | $72 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
863 | $54 | $216 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
305 | $17 | $87 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
222 | $61 | $241 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
101 | $106 | $393 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
86 | $6 | $23 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
65 | $4 | $11 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
62 | $23 | $110 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
54 | $13 | $85 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Singh is a mixed practice specialist, with above-average Medicare volume (top 1% in PA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Singh experienced with alpha 1 proteinase inhibitor injection, 10 mg?
Does Dr. Singh receive payments from pharmaceutical companies?
How do Dr. Singh's costs compare to other vascular surgery physicians in Philadelphia?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology